Citrix Systems Inc
Change company Symbol lookup
Select an option...
CTXS Citrix Systems Inc
RAKR Rainmaker Worldwide Inc
CLB Core Laboratories NV
KERN Akerna Corp
T AT&T Inc
YPPN Yappn Corp
RUSHB Rush Enterprises Inc
CMTL Comtech Telecommunications Corp
BMYMP Bristol-Myers Squibb Co
GOOG Alphabet Inc

Information Technology : Software | Mid Cap Blend
Company profile

Citrix Systems, Inc. offers Enterprise and Service Provider products, which include Workspace Services solutions and Delivery Networking products. The Company's Enterprise and Service Provider products include Cloud Services solutions, and related license updates and maintenance, support and professional services. The Company's NetScaler nCore Technology is an architecture that enables execution of multiple packet engines in parallel. The Company's workspace services include Application Virtualization and virtual desktop infrastructure (VDI), Enterprise Mobility Management and Citrix Workspace Suite. The Company's NetScaler ADC is a software-defined application delivery controller (ADC) and load balancer. The Company's Cloud Services include ShareFile and Citrix Cloud. It provides various ways for customers to receive upgrades, support and maintenance for products, which include Software Maintenance, Subscription Advantage, Technical Support Services and Hardware Maintenance.


Last Trade
2.53 (1.86%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Monoclonal Antibody Therapy Market to Reach USD 350.10 Billion by 2027; Increasing Number of Regulatory Approvals Will Aid Growth, says Fortune Business Insights(TM)

8:17 am ET September 14, 2020 (Globe Newswire) Print

The global monoclonal antibodies therapy market size is projected to reach USD 350.10 billion by the end of 2027. The increasing prevalence of severe diseases such as cancer will create several opportunities for the companies operating in the market. The market was worth USD 123.03 billion in 2019 and will exhibit a CAGR of 14.0% during the forecast period, 2020-2027.

Monoclonal antibodies are immune system proteins that are developed in laboratories. The therapeutic procedures associated with monoclonal antibodies are used in treatment of cancer. The advancements in ongoing clinical trials of drugs as well as treatment options related to these products will aid the growth of the overall market in the coming years.

Request a Sample Copy of the Research Report:

The increasing investment in the research and development of the product will have a positive impact on the growth of the overall market in the forthcoming years. Several monoclonal antibodies are immunotherapeutic, accounting to their ability to treat severe diseases. To put it in clearer terms, this type of therapy makes use of monoclonal antibodies to target the specific cells that are affected by diseases such as cancer.

Highlights of the Report:

-- Analysis of the impact of Covid-19 that the market would face in the near future.

-- In-depth analysis of the growth drivers and obstacles.

-- Profile of all the companies operating in the market.

-- Elaborate data about the dominating region.

-- Competitive landscape consisting of mergers & acquisitions, investments, partnerships, new product launches, opening of new facilities, and new contracts.

Increasing Number of Product Launches Will Aid Growth

The report encompasses several factors that have contributed to the growth of the market in recent years. The increasing investment in the research and development of the product has yielded a few exceptional products in recent times. To tackle severe diseases such as cancer as well as coronavirus, companies are coming up with newer products that will help treat these diseases.

Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit:

In December 2019, Mylan and Biocon announced the launch of new product under the monoclonal antibody therapy category. The company introduced 'Ogivri,' a product that is a biosimilar of trastuzumab. The company will launch the product for commercial use in the United States. The companies' latest product will not just generate substantial monoclonal antibody market revenue but will also have a huge impact on the growth of the overall market in the foreseeable future. The report includes a few of the major products, similar to Ogivri and discusses their impact on the growth of the overall market in the coming years.

North America to Emerge Dominant; Increasing Prevalence of Chronic Diseases Will Aid Growth

The report analyzes the ongoing monoclonal antibody therapy market trends across North America, Latin America, Asia Pacific, the Middle East and Africa, and Europe. Among these regions, the market in North America is projected to emerge dominant in the coming years. The increasing prevalence of chronic diseases has contributed to the growing demand or efficient as well as low-cost therapeutic approaches for treatment.

Quick Buy - Monoclonal Antibody Therapy Market Research Report:

The increasing number of strategic collaborations and funding towards these therapies will also bode well or the growth of the market in this region. As of 2019, the market in North America was worth USD 58.80 billion and this value is projected to increase further in the coming years. The market in Europe will derive growth from the presence of several healthcare reimbursement policies. Moreover, increasing prevalence of diseases such as arthritis as well as inflammatory diseases will contribute to the growth of the market.

List of companies profiled in the Monoclonal Antibody Therapy Market report:

-- AbbVie Inc.

-- Merck & Co., Inc.

-- F.Hoffmann-La Roche Ltd.

-- Bristol-Myers Squibb Company

-- Johnson & Johnson Services, Inc.

-- Daiichi Sankyo Company, Limited

-- Novartis AG

-- Alexion Pharmaceuticals, Inc.

-- Amgen Inc.

-- Others

Industry Developments:

April 2020: GlaxoSmithKline plc announced a collaboration with Vir Biotechnology, Inc. for aimed at developing a treatment against corona virus with the help of Vir's monoclonal antibody platform

Have Any Query? Ask Our Experts:

Monoclonal Antibody Therapy Market Segmentations:

By Type

? Human Monoclonal Antibody

? Humanized Monoclonal Antibody

? Chimeric Monoclonal Antibody

? Murine Monoclonal Antibody

By Application

? Cancer

? Autoimmune Diseases

? Others

By Distribution Channel

? Hospital Pharmacy

? Retail Pharmacy

? Online Pharmacy

By Geography

? North America (the U.S. and Canada)

? Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

? Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

? Latin America (Brazil, Mexico, and Rest of Latin America)

? Middle East& Africa (South Africa, GCC and Rest of Middle East & Africa)

Get your Customized Research Report:

Have a Look at Related Reports:

U.S. Biosimilars Market Share and Global Trend By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies, Others), By Disease Indication (Cancer, Autoimmune Diseases, Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026

Immunology Market Share and Global Trend By Drug Class ( Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal antibody (pAb) ), By Disease Indication ( Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection ), By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Geography Forecast till 2025

Colorectal Cancer Therapeutics Market Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026

Surgical Lights Market Share & Industry Analysis, By Technology (LED, and Halogen), By End User (Hospitals & ASC's, Specialty Clinics, and Others (Procedure Rooms, etc.)) and Regional Forecast, 2019-2026

Spectacles Market Share & Industry Analysis, By Product Type (Spectacles Frames and Spectacle Lenses), By Modality (Prescription and Over-the-counter) By Distribution Channel (Retail Store, Online Store, Ophthalmic Clinics), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights(TM) Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.


US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245


Fortune Business Insights(TM)

LinkedIn | Twitter | Blogs

Press Release:

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.